Immunological changes in patients with chronic heart failure

Иммунологические изменения у пациентов с хронической сердечной недостаточностью
Olga Malgazdarova 1, Bulat Kupenov 1, Akmaral Moldazhanova 1, Zhanat Bekzhigitova 1
More Detail
1 Cardiology Department, National Scientific Medical Center, Astana, Republic of Kazakhstan
J CLIN MED KAZ, Volume 2, Issue 48, pp. 9-13. https://doi.org/10.23950/1812-2892-JCMK-00549
OPEN ACCESS 3366 Views 2354 Downloads
Download Full Text (PDF)

ABSTRACT

Chronic heart failure - symptom complex arising in the outcome of cardiovascular diseases of various etiologies. At the moment heart failure is widespread and has become a pandemic. This fact led to the need to clarify the known mechanisms of pathogenesis and the search for new ways of diagnostics therapy and ultimately to improve methods of monitoring the course of heart failure. The wide diagnostic possibilities of modern medicine did not give a clear understanding of the mechanisms of involvement of the immune system links in the pathogenesis of chronic heart failure. It remains an open question, concluded in the “cytokine theory” of the pathogenesis of chronic heart failure, about the cause-and-effect relationship of the immune response and heart failure.
Keywords: chronic heart failure, left ventricular ejection fraction, cytokines, tumor necrosis factor, a-interleukins

CITATION

Malgazdarova O, Kupenov B, Moldazhanova A, Bekzhigitova Z. Immunological changes in patients with chronic heart failure. Journal of Clinical Medicine of Kazakhstan. 2018;2(48):9-13. https://doi.org/10.23950/1812-2892-JCMK-00549

REFERENCES

  • Belenkov Ju.N., Ageev F.T., et al. Еpidemiologija i prognoz hronicheskoj serdechnoj nedostatochnosti (Epidemiology and Prognosis of Chronic Heart Failure) [in Russian]. Russkij medicinskij zhurnal. 1999; 2:51-56.
  • Belenkov Ju.N., Mareev V.Ju., Ageev F.T. Medikamentoznye puti uluchshenija prognoza u bol’nyh s serdechno jnedostatochnost’ju (Medications for improving the prognosis in patients with heart failure) [in Russian]. M.; «Insajt». 1997:77.
  • Cobn J.N. The management of chronic heart failure. N Engl J Med.1996; 335: 490-8.
  • Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007; 93:1137–1146.
  • Bleumink G.S, Knetsch A.M., Sturkenboom MC JM, Straus SM JM, Hofman A, Deckers J, Witteman JCM, Stricker BHC. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. EurHeartJ England. 2004;25:1614–1619.
  • Wang TJ. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003; 108:977– 982.
  • The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685–691.
  • Redfeid M. et al. Burden of systolic and diastolic ventricular dysfunction in the community appreciating the scope of the heart failure epidemic. JAMA. 2003; 289, 194-202.
  • VanRietEES, Hoes AW, Limburg A, Landman MAJ, Van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail. 2014; 16:772–777.
  • Filippatos G, Parissis JT. Heart failure diagnosis and prognosis in the elderly: the proof of the pudding is in the eating. Eur J Heart Fail. 2011; 1:467–471.
  • Cleland J.G.F, Mac Cown J. Heart failure due ischemic heart disease: epidemiology, pathophysiology and progression. J. Cardiovasc. Pharmacol. 1999; 33(3): 17-29.
  • Klimov A.N., Denisenko A.D., Popov A.V. et al. Lipoprotein antibody immune complexes, their catabolism and role in foam cell formation.Atherosclerosis. 1985; 58: 1-15.
  • Kendall M.J., Zynch K.P., ITjalmerson A., Kjekshus J. P-blockers and sudden cardiac death. Ann. Intern. Med. 1995; 123: 358- 367.
  • M. Hedayat (et al). Proinflamattory cytokines in heart failure: double-edged swords. Heart Fail Rev.2010; 6: 543-562.
  • V.V.Kaljuzhini dr. Patogenez hronicheskoj serdechnoj nedostatochnosti: izmenenie dominirujushhej paradigm (Patogenesis of chronic heart failure: a change in the dominant paradigm) [in Russian]. Bjul. Sib.Med. 2007;4: 71-79.
  • Vasjuk Ju. A. Citokinovaja model’ patogeneza hronicheskoj serdechnoj nedostatochnosti i vozmozhnosti novogo terapevticheskogo podhoda v lechenii dekompensirovannyh bol’nyh (Cytokine model of the pathogenesis of chronic heart failure and the possibility of a new therapeutic approach in the treatment of decompensated patients) [in Russian]. Farmakoterapija v kardiologii. 2006; 4:63-70.
  • Adams V., Jiang H., Yu J. et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is assotiated with exercise intolerance. J Am CollCardiol. 1999, 33: 959-65.
  • Keith M., Geranmayegan A., Sole M. et al. Increased oxidative stress in patients with congestive heart failure. JAmCollCardiol.1998; 31: 1352-6.
  • Anker S.D., Egerer k., Vork H.D. et al. Elevated soluble CD 14 receptore and altereted cytokines in chronic heart failure. AmJCardiol.1997; 79: 1426-30.
  • Hasper D., Hummel L., Kleber F.X. et al. Systemic inflammation in patients with heart failure. Eur Heart J. 1998; 19: 761-5.
  • Bozkurt B., Kribbs S.B., Clubb F.J. et al. Pathophysiologically relevant concentration of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998; 97: 1382-92.
  • Simbircev S.V. Citokiny: klassifikacija i biologicheskie funkcii. Citokinyivospalenie. (Cytokines: classification and biological functions. Cytokines and inflammation.) [in Russian]. 2004;3, 2: 16-22.
  • N.A. Smart et al. Effects of exercise training on IL-6, TNF-α and functional capacity in heart failure. Cardiol.Res.Pract. 2011; 2011: 6.
  • Belenkov Ju.N., MareevV.Ju. Principy racional’nogo lechenija serdechnoj nedostatochnosti (Principles of rational treatment of heart failure) [in Russian]. M.: Media Medika, 2000: 10-16. 
  • McCormack JG, Barr RL, Wolf AA., et al. Ranolazine stimulates glucose oxidation in normoxic, ischaemic and reperfusedischaemic hearts. Circulation. 1996; 93: 135-45.
  • В. Levine, J.Kalman, L.Mayer Elevated circulating levels of tumor necrosis factor in severe chronic failure. New Engl.J.Med. 1990; 32:236-241.
  • A.Abbate, F.N. Salloum, B.W.VanTassel.Alternations in the intrleukin-1/ intrleukin-1 Receptor Antagonist Balance Modulate Cardiac Remodeling followin g Myocardial Infarction in the Mouse. PLos One. 2011; 11: 2792-3.
  • R.Deardorrf, F.G. SpinaleCytokines and Matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med.2009;3, 5: 513-523.
  • O.P. Dudarenko, E.L. Shkol’nik, K.G. Kulikov, M.K. Serova, Ju.A. Vasjuk. Ingibitor sinteza faktora nekroza opuholi-α pentoksifillin v kompleksnoj terapii hronicheskoj serdechnoj nedostatochnosti (The inhibitor of the synthesis of tumor necrosis factor-α pentoxifylline in the complex therapy of chronic cardiac insufficiency) [in Russian]. Racional’najafarmakoterapija v kardiologii.2008; 2:12.
  • Krum H. Tumor Necrosis Factor Alpha Blockade as a Therapeutic Strategy in Heart Failure (RENEVAL and ATTACH): Unsuccessful To Be Specific.Journal of Cardiac Failure. 2002; 6:8.
  • Bergman M.R., Holycross B.J. Pharmacological modulation of myocardial tumor necrosis factor a production phosphodiesterase inhibitore. Pharmacolexpther. 1996; 44: 247-54.
  • Torre-Amione G., Stetson S.S., Farmer J.A. Clinical implications of tumor necrosis factor a antagonist in patients with congestive heart failure. Ann Rheum Dis. 1999; 58 (Suppl 1): 1103-6.
  • Silwa K., Woodiwiss A., KoneV.N.,Candy G., Badenhorst D., Norton G., Zambakides C., Peters F., Essop R. Therapy of ischemic cardiomyopathy with the immunomodulating agent pеntoxifelline: results of a randomized study. Circulation. 2004; 109 (6): 750-5.